Akzo Nobel
This article was originally published in The Gray Sheet
Executive Summary
Dutch conglomerate completes divestiture of the in vitro diagnostics business of its Organon Teknika unit to bioMerieux for about $260 mil. Initially proposed in February, the move will expand bioMerieux' diagnostics revenues to about $1 bil. and allow Organon to focus on its core pharmaceuticals business (1"The Gray Sheet" Feb. 19, 2001, p. 14)